Theodore Pincus to Infliximab
This is a "connection" page, showing publications Theodore Pincus has written about Infliximab.
Connection Strength
0.189
-
Why are only 50% of courses of anti-tumor necrosis factor agents continued for only 2 years in some settings? Need for longterm observations in standard care to complement clinical trials. J Rheumatol. 2006 Dec; 33(12):2372-5.
Score: 0.070
-
Radiographic benefit without clinical improvement in infliximab-treated patients with rheumatoid arthritis: comment on the article by Smolen et al. Arthritis Rheum. 2005 Dec; 52(12):4044-5; author reply 4045-7.
Score: 0.065
-
Eligibility of patients in routine care for major clinical trials of anti-tumor necrosis factor alpha agents in rheumatoid arthritis. Arthritis Rheum. 2003 Feb; 48(2):313-8.
Score: 0.054